Chlorphenamine (Chlorpheniramine)
Brand names: Piriton, Allerief
Chlorphenamine is a sedating (first-generation) antihistamine used for allergic conditions such as urticaria, hay fever and as an adjunct in the emergency treatment of anaphylaxis.
Adult dose
Paediatric dose
Dose adjustments
No numeric adjustment is given. §4.2, verbatim: 'Patients with renal or hepatic impairment should seek doctor's advice prior to taking this medicine.' §4.4 lists 'renal impairment' among the conditions in which chlorphenamine 'should be used with caution'.
No numeric adjustment is given. §4.2, verbatim: 'Patients with renal or hepatic impairment should seek doctor's advice prior to taking this medicine.' §4.4 lists 'hepatic impairment' among the conditions in which chlorphenamine 'should be used with caution'.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- §4.3, verbatim: 'The tablets are contra-indicated in patients who are hypersensitive to antihistamines or to any of the tablet ingredients.'
- §4.3, verbatim: 'The anticholinergic properties of chlorphenamine are intensified by monoamine oxidase inhibitors (MAOIs). The tablets are therefore contra-indicated in patients who have been treated with MAOIs within the last fourteen days.'
- Not a contraindication in this SPC but a §4.4 excipient bar: 'Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.'
- Not contraindications in this SPC but §4.4 CAUTIONS, verbatim: chlorphenamine 'should be used with caution in epilepsy; raised intra-ocular pressure including glaucoma; prostatic hypertrophy; severe hypertension or cardiovascular disease; bronchitis, bronchiectasis and asthma; hepatic impairment; renal impairment.'
- Not a contraindication but a §4.4 population caution: 'Avoid use in elderly patients with confusion.'
- NOT SOURCED HERE: the page's 'Neonates (not recommended)' contraindication. What this SPC says is 'Not recommended for children under the age of 6 years'; it makes no neonatal statement.
Side effects
- Very common (§4.8), nervous system disorders: sedation, somnolence
- Common (§4.8), nervous system disorders: disturbance in attention, abnormal coordination, dizziness, headache
- Common (§4.8), eye disorders: blurred vision
- Common (§4.8), gastrointestinal disorders: nausea, dry mouth
- Common (§4.8), general disorders: fatigue
- Frequency unknown (§4.8), gastrointestinal: vomiting, abdominal pain, diarrhoea, dyspepsia
- Frequency unknown (§4.8), immune system: allergic reaction, angioedema, anaphylactic reactions
- Frequency unknown (§4.8), psychiatric: confusion, excitation, irritability, nightmares, depression - the SPC footnotes these with 'Children and the elderly are more likely to experience the neurological anticholinergic effects and paradoxical excitation'
- Frequency unknown (§4.8), renal and urinary: urinary retention
- Frequency unknown (§4.8), blood and lymphatic: haemolytic anaemia, blood dyscrasias
- Frequency unknown (§4.8), hepatobiliary: hepatitis, including jaundice
- Frequency unknown (§4.8), cardiac: palpitations, tachycardia, arrhythmias; vascular: hypotension
- Frequency unknown (§4.8), respiratory: thickening of bronchial secretions; general: chest tightness
- Frequency unknown (§4.8), skin: exfoliative dermatitis, rash, urticaria, photosensitivity; musculoskeletal: muscle twitching, muscle weakness; metabolism: anorexia; ear and labyrinth: tinnitus
Monitoring
- THIS SPC HAS NO MONITORING SECTION. The entries below are the §4.4 precautions that a prescriber would act on; they are quoted, not inferred.
- Sedation and fitness to drive, §4.4: 'The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment in some patients which may seriously affect ability to drive and use machinery.'
- Duration of use, §4.2: 'Do not use continuously for more than two weeks without consulting a doctor.'
- Older patients, §4.4: 'The elderly are more likely to experience neurological anticholinergic effects'; 'Avoid use in elderly patients with confusion' - and §4.2 advises considering a lower daily maximum of 12 mg in 24 hours.
- Children, §4.4: watch for 'paradoxical excitation (eg. Increased energy, restlessness, nervousness)' rather than sedation.
- Concurrent sedatives and alcohol, §4.4/§4.5: 'Concurrent use with drugs which cause sedation such as anxiolytics and hypnotics may cause an increase in sedative effects'; 'The effects of alcohol may be increased and therefore concurrent use should be avoided.'
- Phenytoin, §4.5: 'Chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity' - watch for phenytoin toxicity if the two are combined.
Clinical monograph
How it works
It is a competitive antagonist at histamine H1 receptors and, owing to its central penetration and antimuscarinic actions, also commonly causes sedation.
Prescribing in practice
- It causes sedation that can impair driving and skilled tasks and is additive with alcohol and other CNS depressants, so warn patients accordingly.
- Its antimuscarinic effects mean it should be used with caution in conditions such as urinary retention, angle-closure glaucoma and prostatic enlargement.
- It is available in oral and injectable forms, with the injection used as an adjunct in the management of anaphylaxis.
Monitoring
Routine monitoring is not generally required; assess for excessive sedation and antimuscarinic effects, particularly in older patients.
Counselling the patient
- Be aware it may cause drowsiness and do not drive or operate machinery if affected.
- Avoid alcohol while taking it.
- It may cause dry mouth, blurred vision or constipation.
Evidence & guidelines
Chlorphenamine is a long-established antihistamine with extensive clinical use in allergic disorders and anaphylaxis.
Reference: RCUK Anaphylaxis Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023